Healthcare stocks declined Friday afternoon, with the NYSE Healthcare Index decreasing 0.2% and the State Street Health Care Select Sector SPDR ETF (XLV) easing 0.1%.
The iShares Biotechnology ETF (IBB) rose 0.5%.
In corporate news, Jazz Pharmaceuticals (JAZZ) shares fell 1.6% after it said Friday that a phase 3 trial of Zepzelca in second-line metastatic small cell lung cancer failed to meet the primary overall survival endpoint, whether used alone or in combination with irinotecan, versus the investigator's choice of chemotherapy.